Associate professor, Radiopharmacist, Faculty of Pharmacy, University of Montpellier

Cyril Fersing is an associate professor of Medicinal Chemistry at the Faculty of Pharmacy of Montpellier since 2018. He also ensures a hospital activity as a radiopharmacist at the Montpellier Cancer Institute (ICM). At the end of his Pharmacy Practice Residency (2013-2018), he received his PharmD degree from Aix-Marseille University. In parallel with his hospital course, he graduated with a PhD in Medicinal Chemistry from Aix-Marseille University in 2018. To match with his current hospital pharmacy activities, bringing together his growing expertise in oncology and his experience in heterocyclic medicinal chemistry, Cyril Fersing directed his research towards the field of cancerology. His research at the ICM consist of the study and optimization of the radiolabelling conditions of theranostic probes; his major research interest within the IBMM focuses on small heterocyclic molecules for targeted enzyme inhibition or degradation.


5 major publications :

C. Fersing, N. Masurier, L. Rubira, E. Deshayes, V. Lisowski. AAZTA-derived chelators for the design of innovative radiopharmaceuticals with theranostic applications. Pharmaceuticals, 2022, 15, 234. DOI: 10.3390/ph15020234.

L.-M. Rečnik, C. Cantelli, C. Fersing, C. Gongora, J.-P. Pouget, V. Lisowski. Synthesis and in vitro antitumour activity of carboplatin analogues containing functional handles compatible for conjugation to drug delivery systems. Bioorganic and Medicinal Chemistry Letters, 2020, 30, 127527. DOI: 10.1016/j.bmcl.2020.127527.

C. Fersing, C. Boudot, R. Paoli-Lombardo, N. Primas, E. Pinault, S. Hutter, C. Castera-Ducros, Y. Kabri, J. Pedron, S. Bourgeade-Delmas, A. Sournia-Saquet, J.-L. Stigliani, A. Valentin, A. Azqueta, D. Muruzabal, A. Destere, S. Wyllie, A. Fairlamb, S. Corvaisier, M. Since, A. Malzert-Fréon, C. Di Giorgio, P. Rathelot, N. Azas, B. Courtioux, P. Vanelle, P. Verhaeghe. Antikinetoplastid SAR study in 3-nitroimidazopyridine series: identification of a novel non-genotoxic and potent anti-T. b. brucei hit-compound with improved pharmacokinetic properties. European Journal of Medicinal Chemistry, 2020, 112668. DOI: 10.1016/j.ejmech.2020.112668.

C. Fersing, C. Boudot, C. Castera-Ducros, E. Pinault, S. Hutter, R. Paoli-Lombardo, N. Primas, J. Pedron, L. Seguy, S. Bourgeade-Delmas, A. Sournia-Saquet, J.-L. Stigliani, J.-Y. Brossas, L. Paris, A. Valentin, S. Wyllie, A. Fairlamb, E. Boutet-Robinet, S. Corvaisier, M. Since, A. Malzert-Fréon, A. Destere, D. Mazier, P. Rathelot, B. Courtioux, N. Azas, P. Verhaeghe, P. Vanelle. 8-Alkynyl-3-nitroimidazo[1,2-a]pyridines display potent in vitro activity toward T b. brucei and T. cruzi after bioactivation by type 1 nitroreductases. European Journal of Medicinal Chemistry, 2020, 112558. DOI: 10.1016/j.ejmech.2020.112558.

C. Fersing, A. Bouhlel, C. Cantelli, P. Garrigue, V. Lisowski, B. Guillet. A comprehensive review of non-covalent radiofluorination approaches using aluminum [18F]fluoride: will [18F]AlF replace 68Ga for metal chelate labeling? Molecules, 2019, 24, 2866. DOI: 10.3390/molecules24162866.